We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
After months of investor apathy, Bristol-Myers Squibb's business is finally starting to blossom. One of his most recent ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...